Key Findings:
- Tumor-cell MHC class II (HLA-DRA) expression was associated with an adaptive immune microenvironment in triple-negative breast cancer.
- High tumor-cell HLA-DR expression was associated with response to immune checkpoint blockade.
- In pembrolizumab-treated cohorts, responders had higher proportions of HLA-DRA-expressing tumor cells and increased local adaptive immune signatures.